State Street’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-2,020,917
| Closed | -$18.1M | – | 3758 |
|
|
2016
Q3 | $18.1M | Buy |
2,020,917
+73,828
| +4% | +$525K | ﹤0.01% | 1836 |
|
|
2016
Q2 | $10.5M | Buy |
1,947,089
+580,140
| +42% | +$2.97M | ﹤0.01% | 2199 |
|
|
2016
Q1 | $6.29M | Sell |
1,366,949
-1,494,941
| -52% | -$6.01M | ﹤0.01% | 2432 |
|
|
2015
Q4 | $14.9M | Sell |
2,861,890
-549,558
| -16% | -$3.19M | ﹤0.01% | 1933 |
|
|
2015
Q3 | $20.6M | Buy |
3,411,448
+384,068
| +13% | +$4.71M | ﹤0.01% | 1719 |
|
|
2015
Q2 | $47.8M | Buy |
3,027,380
+159,959
| +6% | +$1.94M | 0.01% | 1301 |
|
|
2015
Q1 | $31.2M | Sell |
2,867,421
-157,705
| -5% | -$1.61M | ﹤0.01% | 1520 |
|
|
2014
Q4 | $31.8M | Buy |
3,025,126
+598,779
| +25% | +$5.85M | ﹤0.01% | 1474 |
|
|
2014
Q3 | $23.3M | Buy |
2,426,347
+179,474
| +8% | +$1.83M | ﹤0.01% | 1627 |
|
|
2014
Q2 | $26M | Sell |
2,246,873
-338,107
| -13% | -$3.08M | ﹤0.01% | 1631 |
|
|
2014
Q1 | $25.8M | Buy |
2,584,980
+524,629
| +25% | +$7.58M | ﹤0.01% | 1582 |
|
|
2013
Q4 | $26.8M | Buy |
2,060,351
+176,794
| +9% | +$2.43M | ﹤0.01% | 1548 |
|
|
2013
Q3 | $28.1M | Buy |
1,883,557
+1,004,520
| +114% | +$12M | ﹤0.01% | 1487 |
|
|
2013
Q2 | $8.22M | Buy |
+879,037
| New | +$5.95M | ﹤0.01% | 2165 |
|
State Street's RPTP Position: Q4 2016 in Review
State Street sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 2,020,917 shares — an estimated $18.1M sold.
State Street first reported a position in RPTP in Q2 2013 and held it in 14 quarters. The position peaked at $47.8M in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.
- State Street reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
- State Street sold 2,020,917 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $18.1M.
- State Street first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q2 2013 and held it in 14 quarters.
- State Street's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $47.8M in Q2 2015.
- 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.
Based on State Street's 13F filing for Q4 2016, filed 9 Feb 2017.